Literature DB >> 1467311

Germ-line splicing mutation of the p53 gene in a cancer-prone family.

S G Warneford1, L J Witton, M L Townsend, P B Rowe, R R Reddel, L Dalla-Pozza, G Symonds.   

Abstract

Li-Fraumeni syndrome is a rare autosomal dominant susceptibility to a variety of cancers including carcinomas of the breast and the adrenal cortex, tumors of brain and muscle tissue, and leukemias. Affected individuals develop cancer at a young age and often at multiple primary sites. A study has been conducted into the genetic basis of cancer in a particular Li-Fraumeni syndrome family. Examination of p53 as a candidate susceptibility gene revealed that, in two affected individuals, there was an aberrant larger transcript of 3.6 kilobases present in both tumor and constitutional material in addition to the normal-sized 2.8-kilobase transcript. The additional transcript was not found in three unaffected family members. S1 nuclease mapping localized the insertion toward the 5' end of the p53 transcript near exons 4 and 5, and sequencing revealed a point mutation in the splice donor site of intron 4 in the germ-line of the two affected individuals, which accounted for the presence of the larger transcript. The same splicing mutation was also detected in two obligate carriers and was not found in two unaffected individuals. As no mutations were detected in exons 5-8 in either tumor examined, the second p53 allele was most likely lost during tumorigenesis in both tumors. The demonstration of a germ-line splicing mutation in affected individuals from a Li-Fraumeni syndrome family provides for a novel mechanism of p53 inactivation not seen previously in other affected families, in whom the mutations have all been missense.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467311

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  13 in total

1.  Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.

Authors:  Jonathan D Wasserman; Ana Novokmet; Claudia Eichler-Jonsson; Raul C Ribeiro; Carlos Rodriguez-Galindo; Gerard P Zambetti; David Malkin
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

2.  Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts.

Authors:  E M Rogan; T M Bryan; B Hukku; K Maclean; A C Chang; E L Moy; A Englezou; S G Warneford; L Dalla-Pozza; R R Reddel
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

Review 3.  Tumors associated with p53 germline mutations: a synopsis of 91 families.

Authors:  P Kleihues; B Schäuble; A zur Hausen; J Estève; H Ohgaki
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

4.  Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors.

Authors:  J M Varley; G McGown; M Thorncroft; L A James; G P Margison; G Forster; D G Evans; M Harris; A M Kelsey; J M Birch
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

5.  Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants.

Authors:  Emilia M Pinto; Kara N Maxwell; Hadeel Halalsheh; Aaron Phillips; Jacquelyn Powers; Suzanne MacFarland; Michael F Walsh; Kelsey Breen; Maria N Formiga; Richard Kriwacki; Kim E Nichols; Roya Mostafavi; Jinling Wang; Michael R Clay; Carlos Rodriguez-Galindo; Raul C Ribeiro; Gerard P Zambetti
Journal:  Mol Cancer Res       Date:  2021-10-21       Impact factor: 6.333

6.  Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.

Authors:  T Frebourg; N Barbier; Y X Yan; J E Garber; M Dreyfus; J Fraumeni; F P Li; S H Friend
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

7.  Telomere elongation in immortal human cells without detectable telomerase activity.

Authors:  T M Bryan; A Englezou; J Gupta; S Bacchetti; R R Reddel
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

8.  HP1-mediated formation of alternative lengthening of telomeres-associated PML bodies requires HIRA but not ASF1a.

Authors:  Wei-Qin Jiang; Akira Nguyen; Ying Cao; Andy C-M Chang; Roger R Reddel
Journal:  PLoS One       Date:  2011-02-15       Impact factor: 3.240

9.  Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins.

Authors:  Wei-Qin Jiang; Ze-Huai Zhong; Akira Nguyen; Jeremy D Henson; Christian D Toouli; Antony W Braithwaite; Roger R Reddel
Journal:  J Cell Biol       Date:  2009-05-25       Impact factor: 10.539

Review 10.  Analytical methods for inferring functional effects of single base pair substitutions in human cancers.

Authors:  William Lee; Peng Yue; Zemin Zhang
Journal:  Hum Genet       Date:  2009-05-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.